The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,000
Angeles, C. V., Velez, A., Rios, J., Laxa, B., Shum, D., Ruiz, P. D., Shen, Y., Ostrovnaya, I., Gularte-Mérida, R., Nacev, B. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2486 · Cited by 13
Lou, S., Chen, H., Cui, Z., Zhang, X., Zhu, C., Zhou, L., Ou, Y., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516449 · Cited by 14
Proteomics in pancreatic cancer
Cai, F., Gu, Y., Ling, Y., Yi, G., Zang, S., Su, T., Liu, Y., Li, A., Wang, D., Zhao, W., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00805-y · Cited by 19
“For patients whose disease progresses on these regimens, alternative regimens or second-line options, such as liposomal irinotecan combined with 5-FU, may be considered if not previously administered [24].”
Zhong, J. Y., Wu, L., Song, Z., Xing, N., Cui, J., Li, X., Fei, K., Tang, D., Dang, Q., Liang, C., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.012 · Cited by 14
Erlangga, Z., Wolff, K., Poth, T., Peltzer, A., Nahnsen, S., Spielberg, S., Timrott, K., Woller, N., Kühnel, F., Manns, M. P., et al. (2019) · Cancers · doi:10.3390/cancers11121904 · Cited by 16
Ettrich, T. J., Sturm, N., Güthle, M., Hüttner, F. J., & Perkhofer, L. (2022) · Visceral Medicine · doi:10.1159/000521631 · Cited by 14
Tao, G., Dagher, F., Li, L., Singh, R., Hu, M., & Ghose, R. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113246 · Cited by 14
Management of elderly patients with unresectable pancreatic cancer
Kobayashi, S., Ueno, M., Ishii, H., & Furuse, J. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac101 · Cited by 14
Xu, J. H., Xie, L., Sun, X., Liu, K., Liang, X., Cai, Z., Tang, X., & Guo, W. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3546 · Cited by 14
Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies
Wang, Z., Wu, B., Nie, G., Wei, J., & Li, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216138 · Cited by 15
Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study
Gueiderikh, A., Tarabay, A., Abdelouahab, M., Smolenschi, C., Tanguy, M., Valéry, M., Malka, D., Pudlarz, T., Fuerea, A. C., Boige, V., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12016-z · Cited by 14
Toledo, B., Deiana, C., Scianò, F., Brandi, G., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2319340 · Cited by 15
“OS is usually between 3 and 9 months, and ORR varies between 10% and 20% for combination treatments to less than 10 for the monothera-pies arm [23–26] (Table 2).”
BackgroundYu, I., & Cheung, W. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/1863535 · Cited by 14
“0001) compared to 5-FU/leucovorin alone [24].”
Lee, K., Bang, K., Yoo, C., Hwang, I., Jeong, J. H., Chang, H.-M., Oh, D., Song, T. J., Park, D. H., Lee, S. S., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.190 · Cited by 14
Self-citationPostoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer
Wu, H., Guo, J., Yang, S., Tien, Y., & Kuo, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081115 · Cited by 14
Simionato, F., Zecchetto, C., Merz, V., Cavaliere, A., Casalino, S., Gaule, M., D’Onofrio, M., Malleo, G., Landoni, L., Esposito, A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920947969 · Cited by 14
Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
Parrasia, S., Zoratti, M., Szabó, I., & Biasutto, L. (2020) · Cellular Physiology and Biochemistry · doi:10.33594/000000326 · Cited by 14
Future directions in drug development in pancreatic cancer
Lambert, A., Conroy, T., & Ducreux, M. P. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.002 · Cited by 14
How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?
Gilabert, M., Raoul, J., & Rousseau, F. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.08.007 · Cited by 14
Self-citationHecht, J. R., Papadopoulos, K. P., Falchook, G. S., Patel, M. R., Infante, J. R., Aljumaily, R. M., Wong, D. J. L., Autio, K. A., Wainberg, Z. A., Bauer, T. M., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01000-6 · Cited by 14
Self-citationBuilding towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 14
Mie, T., Sasaki, T., Takeda, T., Fukuda, K., Furukawa, T., Yamada, Y., Kasuga, A., Matsuyama, M., Ozaka, M., & Sasahira, N. (2021) · Pancreas · doi:10.1097/mpa.0000000000001801 · Cited by 14
“Recently, the efficacy of nanoliposomal irinotecan with fluorouracil and folinic acid after gemcitabine-based first-line therapywas reported.(23)We expect that thewidespread use of nanoliposomal irinotecanwith fluorouracil and folinic acid will improve real-world OS, especially in patients who cannot tolerate second-l…”
BackgroundYu, H.-Y., Lee, C.-Y., Lin, L.-G., Chao, Y., & Li, C.-P. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000650 · Cited by 14
Self-citationWang‐Gillam, A., Hoff, D. D. V., Siveke, J. T., Hubner, R. A., Belanger, B., Pipas, J. M., & Chen, L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1607 · Cited by 14
Self-citationRoth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 19
Self-citationEfficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model
Yoshida, T., Kaibori, M., Fujisawa, N., Ishizuka, M., Sumiyama, F., Hatta, M., Kosaka, H., Matsui, K., Suzuki, K., Akama, T. O., et al. (2022) · Nanomaterials · doi:10.3390/nano12081364 · Cited by 13
Möhring, C., Graffe, F. J. F., Bartels, A., Sadeghlar, F., Zhou, T., Mahn, R., Marinova, M., Feldmann, G., Brossart, P., Glowka, T. R., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-632 · Cited by 13
“The prospective NAPOLI-1 trial revealed the same impact of dose modification on OS, which is important information for the treating physicians who must determine the balance between therapy effectiveness and toxicity (28).”
InfluentialZhou, K., Strunk, H. M., Dimitrov, D., Vidal-Jové, J., Gonzalez-Carmona, M. A., Essler, M., Jin, C., Mei, Z., Zhu, H., & Marinova, M. (2023) · International Journal of Hyperthermia · doi:10.1080/02656736.2023.2295812 · Cited by 13
“In second-line treat-ment, the combination of 5-FU/LV with nanoliposomal irinotecan (nal-IRI) has been shown to be effective following gemcitabine-based therapy [8].”
InfluentialKodama, T., Imajima, T., Shimokawa, M., Otsuka, T., Kawahira, M., Nakazawa, J., Hori, T., Shibuki, T., Arima, S., Ido, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63172-y · Cited by 14
“The proportions of patients with prior 5-FU and platinum were also lower, but there was no significant difference when compared with other clinical trials 13 .”
InfluentialKim, M., Kim, M., Kim, S. J., An, S., Park, H., Park, H., Lee, J. H., Song, K.-B., Hwang, D. W., Chang, S., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0416-8 · Cited by 14
Palacio, S., Hosein, P. J., dos Reis, I. M., Akunyili, I. I., Ernani, V., Pollack, T., MacIntyre, J., Restrepo, M. H., Merchan, J. R., & Lima, C. M. R. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.10.12 · Cited by 13
Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer
Xu, J.-Z., Wang, W.-Q., Zhang, S.-R., Xu, H., Wu, C., Qi, Z.-H., Gao, H.-L., Li, S., Ni, Q.-X., Yu, X., et al. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180413101722 · Cited by 13
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 15
Second line treatment options for pancreatic cancer
Passero, F. C., & Saif, M. W. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369955 · Cited by 13
“Although the positive results of the NAPOLI-1 trial are encouraging, with the ability to offer newer and effective therapeutic options for the second-line treatment of patients with pancreatic cancer, there remain many unanswered questions that are vital to the management of APC in the years to come.”
Skelton, W. P., Parekh, H. D., Starr, J. S., Trevino, J. G., Cioffi, J. L., Hughes, S. J., & George, T. J. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-0021-z · Cited by 13
“The recent approval of nanoliposomal irinotecan with 5-FU helped establish that a survival advantage can be seen in select patients treated in the second-line setting [95].”
BackgroundManagement of hyperbilirubinaemia in pancreatic cancer patients
Álvarez-Gallego, R., Carrato, A., Adeva, J., Alés, I., Prados, S., Valladares, M., Macarulla, T. M., Muñoz, A., & Hidalgo, M. M. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.078 · Cited by 13
Self-citationDeodhar, S., Dash, A. K., North, E. J., & Hulce, M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01745-6 · Cited by 13
Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma
Bisht, S., Brossart, P., & Feldmann, G. (2018) · Oncology Research and Treatment · doi:10.1159/000493868 · Cited by 13
Khushman, M. M., Patel, G., Perry, J., Abdul-Rahim, O., Frankel, A., Cameron, D., Taylor, W. R., Rocconi, R., Abushahin, L. I., Nelson, C. L., et al. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_729_18 · Cited by 13
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 14
Miki, M., Lee, L., Hisano, T., Sugimoto, R., & Furukawa, M. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13669 · Cited by 13
(2017) · Annals of Oncology · doi:10.1093/annonc/mdx244 · Cited by 13
Yu, K. H., Park, J., Mittal, A., Abou‐Alfa, G. K., Dika, I. E., Epstein, A. S., Ilson, D. H., Kelsen, D. P., Ku, G. Y., Li, J., et al. (2022) · Cancer · doi:10.1002/cncr.34269 · Cited by 12
“2965 Cancer August 1, 2022 use this assay to guide therapy in multiple lines is of increasing importance as active frontline regimens allow more patients to receive subsequent lines of therapy, and with the approval of regimens in this setting.(35) Although the current study design provides strong evidence that the as…”
BackgroundSelf-citationLi, P., Zhang, H., & Dai, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217274 · Cited by 14
Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy
Escalera-Anzola, S., Rosado, M., Yang, Y., Sánchez, D. P., Pedro-Liberal, C. S., & Acedo, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116685 · Cited by 12
Basingab, F. S., Alshahrani, O. A., AlAnsari, I., Almarghalani, N. A., Alshelali, N. H., Alsaiary, A. H., Alharbi, N. M., & Zaher, K. A. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s501448 · Cited by 13
“131 Similarly, Vyxeos ® is a liposomal formulation that combines daunorubicin and cytarabine in a 1:5 molar ratio, enhancing drug delivery to leukemia cells while minimizing toxicity.”
InfluentialOrlandi, E., Guasconi, M., Romboli, A., Giuffrida, M., Toscani, I., Anselmi, E., Porzio, R., Madaro, S., Vecchia, S., & Citterio, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062620 · Cited by 12
“This regimen improved median OS compared to 5-FU monotherapy and is a viable choice for patients with adequate physical performance [5].”
Gemcitabine-resistant pancreatic cancer: a second-line option
Oettle, H., & Lehmann, T. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01035-1 · Cited by 12
Management of Metastatic Pancreatic Adenocarcinoma
Cheema, A. R., & O'Reilly, E. M. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.011 · Cited by 12
“Patients were randomly assigned to receive liposomal irinotecan with or without 5-FU/LV or 5-FU/LV alone.(50) OSwas the principal endpoint of the study.”
MethodXue, T., Xu, P., Padelford, J., Xue, X., Wu, A. Y., Li, Y., & Wang, L. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01231-9 · Cited by 12
Ng, S., Healey, A. J., Sontum, P. C., Kvåle, S., TORP, S. H., Sulheim, E., Hoff, D. D. V., & Han, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.016 · Cited by 12
Pang, J., Zhuang, B., & Zhang, L. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127467 · Cited by 12
Varadhachary, G. R., & Wolff, R. A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.015586 · Cited by 12
Chung, K. H., Ryu, J. K., Son, J. H., Lee, J. W., Jang, D. K., Lee, S. H., & Kim, Y. (2016) · Gut and Liver · doi:10.5009/gnl16307 · Cited by 12
“2 months).(19) Chemically, capecitabine is oral fluoropyrimidine carbamate designed to generate 5-FU preferentially in tumor tissue, through exploitation of high intratumoral concentrations of thymidine phosphorylase.”
BackgroundEmerging protein kinase inhibitors for treating pancreatic cancer
Furuse, J., & Nagashima, F. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1293648 · Cited by 12
“Recently, in a phase III trial, nanoliposomal irinotecan with 5-FU and folinic acid yielded survival benefit as compared to 5-FU and folinic acid in patients with metastatic pancreatic cancer who had previously received gemcitabine-based therapy [17].”
BackgroundPhysiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
Fan, Y., Mansoor, N., Ahmad, T., Khan, R. A., Czejka, M. J., Sharib, S., Yang, D., & Ahmed, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18380 · Cited by 12
Bullock, A. J., Stuart, K. E., Jacobus, S. J., Abrams, T. A., Wadlow, R. C., Goldstein, M., & Miksad, R. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.06 · Cited by 12
Self-citationDuktales Adenokarzinom des Pankreas
Gallmeier, E., & Gress, T. M. (2018) · Der Internist · doi:10.1007/s00108-018-0460-z · Cited by 12
Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer
Wong, H. C. Y., Kwan Yu, L. A. M., Chong, C. C. N., Chan, A. W. H., & Chan, S. L. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1595047 · Cited by 12
Iede, K., Yamada, T., Kato, R., Ueda, M., Tsuda, Y., Nakashima, S., Ohta, K., Matsuyama, J., Ikenaga, M., & Tominaga, S. (2019) · Cancer Reports · doi:10.1002/cnr2.1215 · Cited by 12
Tsang, E. S., Spratlin, J. L., Cheung, W. Y., Kim, C., Kong, S., Xu, Y., & Gill, S. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000625 · Cited by 12
Koeller, J. M., Surinach, A., Arikian, S. R., Zivkovic, M., Janeczko, P., Cockrum, P. C., & Kim, G. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944052 · Cited by 12
Chen, L., Macarulla, T. M., Blanc, J., Mirakhur, B., de Jong, F. A., Belanger, B., Bekaii‐Saab, T., & Siveke, J. T. (2020) · Pancreatology · doi:10.1016/j.pan.2020.10.029 · Cited by 12
Self-citationNovel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
Cortinovis, D. L., Bidoli, P., Canova, S., Colonese, F., Gemelli, M., Lavitrano, M., Banna, G. L., Liu, S. V., & Morabito, A. (2021) · Cancers · doi:10.3390/cancers13051152 · Cited by 12
Pancreatic adenocarcinoma: Beyond first line, where are we?
Cherri, S., Noventa, S., & Zaniboni, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1847 · Cited by 13
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12
Clinical applications of nanostructured drug delivery systems
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102198-9.00004-1 · Cited by 12
Regorafenib in Patients with Refractory Metastatic Pancreatic Cancer: A Phase II Study (RESOUND)
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Pressiani, T., Smiroldo, V., Prete, M. G., Spaggiari, P., Personeni, N., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0480 · Cited by 12
Zhu, J., Xiao, Y., Huang, X., Niu, Q., Zeng, L., Lin, S., Jiang, M., Huang, T., Chen, H., Xie, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202511337 · Cited by 13
Self-citationTargeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Ozawa, H., Takahashi, K., Motegi, T., Jacobi, J. J., Bhattacharya, A., Shigeta, K., Takamori, S., Onishi, M., Luan, Z., Fukuda, K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2333 · Cited by 11
“Patients with unresectable and recurrent disease have had few therapeutic options, largely consisting of systemic chemotherapy (4, 5).”
Siolas, D., Morrissey, C., & Oberstein, P. E. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000052 · Cited by 11
“6 months.(66) Further studies are needed to determine if additional combinations or targets in this pathway may provide greater”
BackgroundColloca, G. A. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13598 · Cited by 11
Fu, Z., Zhang, X., Gao, Y., Fan, J., & Gao, Q. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1320 · Cited by 11
Yang, T., Han, Y., Chen, J., Liang, X., & Sun, L. (2023) · Biomedicines · doi:10.3390/biomedicines11112874 · Cited by 12
Self-citationMorales, M. G., Visa, L., Vázquez, E., Feliú, J., Shahi, P. K., Sáez, B. L., Hernández, B. L. D. S. V., Macarulla, T. M., & Sarrió, R. G. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03386-8 · Cited by 11
“In patients with good general and functional status (ECOG 0–1) who had progressed on a gemcitabine-based regimen, the phase III NAPOLI trial administered a second line of treatment with nanoliposomal irinotecan (nal-IRI), 5-FU, and leucovorin (NalIRI/5-FU/ LV) [59].”
MethodSelf-citationMultidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12
Christensen, T. D., Maag, E., Theile, S., Madsen, K., Lindgaard, S. C., Hasselby, J. P., Nielsen, D. L., Johansen, J. S., & Chen, I. M. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103489 · Cited by 12
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma
Hsueh, C.-T., Selim, J. H., Tsai, J. Y., & Hsueh, C.-T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.7080 · Cited by 11
Merz, V., Cavaliere, A., Messina, C. G. M., Salati, M., Zecchetto, C., Casalino, S., Milella, M., Caffo, O., & Melisi, D. (2020) · Cancers · doi:10.3390/cancers12051131 · Cited by 11
Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach
Winer, A., & Dotan, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00892-7 · Cited by 11
Chiu, T., Su, Y., Yang, S., Li, C., Bai, L., Chiang, N., Chuang, S., Shan, Y., Chan, D., Chen, L., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211058255 · Cited by 11
Self-citationAnti-Tumor and Anti-Metastasis Effects of Berbamine-Loaded Lipid Nanoparticles on Pancreatic Cancer
Tang, Z., Yi-Chun, N., Xu, Z., Shi, Y., Liu, Y., Fu, W., Zheng, M., He, H., & Wu, T. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220501161636 · Cited by 11
Wei, T.-H., Ye, B.-W., Wu, P.-S., Li, C., Chao, Y., Lee, P., Huang, Y., Lee, K., & Hou, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268920 · Cited by 11
“The long-term survival of patients with advanced pancreatic adenocarcinoma has been increasing over time as newer chemotherapy regimens, such as FOLFIRINOX [25], gemcitabine/nab-paclitaxel [24], and nanoliposomal irinotecan in combination with 5-FU and leucovorin [23], have been applied to these patients.”
BackgroundSelf-citationWang, Y., Wang, B., Xiang, L., Deng, J., Xu, B., He, P., Pu, W., Wang, H., Fan, Y., & Chen, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016647 · Cited by 9
Zhang, J., Wang, B., Wang, H., Wang, Z., Zhang, P., Huang, X., Qian, H., Huang, D., Chen, W., & Zhong, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.030 · Cited by 11
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
Sarfraz, H. R., Saha, A., Jhaveri, K. S., & Kim, D. W. (2023) · Current Oncology · doi:10.3390/curroncol30060404 · Cited by 11
Metastatic Pancreatic Cancer: Where Are We?
Hernández-Blanquisett, A., Quintero-Carreño, V., Martínez‐Ávila, M. C., Porto, M., Barbur, M. C. M., & Buendía, E. (2024) · Oncology Reviews · doi:10.3389/or.2023.11364 · Cited by 13
Hua, J., Shi, S., Liang, D., Liang, C., Meng, Q., Zhang, B., Ni, Q., Xu, J., & Yu, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s166405 · Cited by 11
The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery
Paredes, K. O., Ruíz-Cabello, J., Alarcón, D. I., & Filice, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00015-0 · Cited by 11
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
Yang, F., Jin, C., Fu, D., & Warshaw, A. L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2839 · Cited by 11
Weng, C., Lin, Y., & Cheng, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091369 · Cited by 12
Park, S. J., Kim, H., Shin, K., Lee, M. A., & Hong, T. H. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i11.1021 · Cited by 11
Pu, N., Yin, H., Chen, Q., Zhang, J., Wu, W., & Lou, W. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1045 · Cited by 11
Iede, K., Yamada, T., Koh, M., Ueda, M., Tsuda, Y., Nakashima, S., Ohta, K., Tanida, T., Matsuyama, J., Ikenaga, M., et al. (2022) · Pancreas · doi:10.1097/mpa.0000000000002013 · Cited by 11
Gong, J., Thomassian, S., Kim, S., Gresham, G. K., Moshayedi, N., Ye, J. Y., Yang, J. C., Jacobs, J. P., Lo, S., Nissen, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19401-3 · Cited by 11
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
Ramaswamy, A., Srinivas, S., Chaudhari, V. A., BHARGAVA, P. G., BHANDARE, M. S., Shrikhande, S. V., & Ostwal, V. S. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1367 · Cited by 10
“Wang-Gillam A, Li CP, and Bodoky G, et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet 387(10018) 545–557 https://doi.org/10.1016/S0140-6736(15)00986-1 27.”
BackgroundInfluentialKumar, S., Singh, S. K., Srivastava, P., Suresh, S., Rana, B., & Rana, A. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.003 · Cited by 10
Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications
Boggio, E. M., Gigliotti, C. L., Stoppa, I., Pantham, D., Sacchetti, S., Rolla, R., Grattarola, M., Monge, C., Pizzimenti, S., Dianzani, U., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030937 · Cited by 10
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Su, Y., Chiang, N., Chiu, T., Huang, C., Hsu, S., Lin, H., Yang, S., Yang, Y., Chou, W., Chen, Y., et al. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100696 · Cited by 11
“In recent years, second-line treatment with liposomal irinotecan (nal-IRI) plus fluorouracil and LV (5-FU/LV) has been recommended by the National Comprehensive Cancer Network (NCCN) guidelines and approved by the Taiwan National Health Insurance [6].”
BackgroundMethodSelf-citationAdak, D., Ray, P., & Setua, S. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100447 · Cited by 11
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
